From ICI to ICU: Ipilimumab and Nivolumab-Induced Immune Checkpoint Inhibitor Colitis

Dig Dis Sci. 2022 Mar;67(3):800-803. doi: 10.1007/s10620-021-07100-4. Epub 2021 Jun 22.

Authors

Wendy Zhou¹, Joseph Frye², Camille Soroudi³, George Triadafilopoulos⁴, Rani Berry⁴

Affiliations

¹ Department of Medicine, Santa Clara Valley Medical Center, San Jose, CA, USA. wendyzhou16@gmail.com.
² Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
³ Department of Medicine, University of California Los Angeles Medical Center, Los Angeles, CA, USA.
⁴ Department of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA.

PMID: 34159488
DOI: 10.1007/s10620-021-07100-4

No abstract available

MeSH terms

Colitis* / chemically induced
Humans
Immune Checkpoint Inhibitors / adverse effects
Intensive Care Units
Ipilimumab / adverse effects
Nivolumab* / adverse effects

Substances

Immune Checkpoint Inhibitors
Ipilimumab
Nivolumab